Top Medical News
Tristan Manalac, 4 days ago
Blephasteam and TheraPearl, two warm compress medical devices worn over the eyes, achieve comparable efficacy in treating mild to moderate meibomian gland dysfunction (MGD), according to a recent study.
4 days ago
Infants with hyperglycaemia are at an increased risk of having retinopathy of prematurity (ROP), a recent study has found. Meanwhile, no such effect was observed for serum levels of glycated albumin (GlyA).
6 days ago
Patients with refractory uveitic macular edema are more likely to achieve complete response with tocilizumab than with antitumour necrosis factor alpha (anti-TNF-α) drugs, as reported in a study.
20 Nov 2021
Cataract surgery is safe and does not confer an increased risk of developing late age-related macular degeneration over 10 years of follow-up, according to a study.
17 Nov 2021
Children with retinopathy of prematurity (ROP) who receive antivascular endothelial growth factor (anti-VEGF) therapy fare better than their counterparts who undergo primary laser treatment, a study has found.
Jairia Dela Cruz, 15 Nov 2021
The varenicline-containing nasal spray OC-01 appears beneficial in the treatment of dry eye disease, producing improvements in natural tear film production and patient-reported symptoms with a tolerable safety profile, as shown in the phase III trial ONSET-2.
Kanas Chan, 15 Nov 2021
Unprecedented quarantine and social distancing measures implemented during the coronavirus disease 2019 (COVID-19) pandemic have resulted in a “myopia boom” in school-aged children in Hong Kong, according to results of a population-based study by the Chinese University of Hong Kong (CUHK).
Dr. Karl Csaky, Dr. Charles Wykoff, Dr. Jeffrey Heier, 08 Apr 2021
Intravitreal injections with anti-vascular endothelial growth factor (VEGF) agents are associated with significant treatment burden for patients with diabetic macular oedema (DME) and neovascular age-related macular degeneration (nAMD). At the Angiogenesis, Exudation, and Degeneration 2021 Virtual Congress, Dr Karl Csaky of Retina Foundation of the Southwest, Dallas, Texas, US, Dr Charles Wykoff of Retina Consultants of Texas, Houston, Texas, US, and Dr Jeffrey Heier of Ophthalmic Consultants of Boston, Boston, Massachusetts, US, presented results of four phase III trials that compared the efficacy and safety of the investigational bispecific antibody, faricimab, administered at up to Q16W dosing intervals, vs the decoy VEGF-A/placental growth factor (PIGF) receptor aflibercept at Q8W dosing intervals, in patients with retinal vascular diseases.
Roshini Claire Anthony, 28 Jun 2020
Roxadustat treatment for anaemia in patients with dialysis-dependent chronic kidney disease (DD CKD) does not come with an increased risk of ophthalmic abnormalities, according to a phase III trial conducted in Japan.